Drugs / STI-9199
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05372783 | Apr 2023 → Jun 2024 | COVID-19 | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-9199 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05372783 ↗ |
| Modality | Monoclonal antibody | “STI-9199 is a fully human monoclonal antibody” NCT05372783 ↗ |
| Route | Intranasal | “administered intranasally” NCT05372783 ↗ |